CDK Inhibitors: Potential Cancer Therapeutic Applications and Side Effects

Target Name: Cyclin-dependent kinase inhibitor

NCBI ID: P6323

Cyclin-dependent kinase inhibitor

Other Name(s): CDK Inhibitor

CDK Inhibitors: Potential Cancer Therapeutic Applications and Side Effects

Cyclin-dependent kinase (CDK) inhibitors are a class of drugs that work by inhibiting the activity of CDK, which is a protein that plays a key role in cell division and growth. CDK inhibitors have been shown to be effective in treating various types of cancer, including breast, lung, and ovarian cancer. In addition to their potential cancer therapeutic applications, CDK inhibitors have also been identified as potential drug targets or biomarkers.

CDK inhibitors work by inhibiting the activity of the enzyme cyclin D1, which is a key component of the CDK complex. The CDK complex is a protein that consists of several subunits, including the CDK1 subunit, which is the most abundant, and the CDK2 subunit, which is less abundant. The CDK1 subunit is responsible for activating the CDK2 subunit, which then activates the entire CDK complex and plays a key role in cell division and growth.

CDK inhibitors work by inhibiting the activity of the CDK1 subunit of the CDK complex. This inhibition prevents the CDK2 subunit from being activated, which in turn inhibits the entire CDK complex and results in the inhibition of cell division and growth. CDK inhibitors are effective in treating various types of cancer because they can inhibit the activity of the CDK complex and result in the inhibition of cell division and growth.

CDK inhibitors have been shown to be effective in treating various types of cancer. For example, research has shown that CDK inhibitors are effective in treating breast cancer, which is the second leading cause of cancer death in women. In addition to breast cancer, CDK inhibitors have also been shown to be effective in treating lung cancer and ovarian cancer.

In addition to their potential cancer therapeutic applications, CDK inhibitors have also been identified as potential drug targets or biomarkers. For example, the CDK inhibitor PD-03129 has been shown to be effective in treating pancreatic cancer, and a potential drug candidate for the treatment of ovarian cancer. In addition, the CDK inhibitor NEDD8 has been shown to be a potential biomarker for the diagnosis and prognosis of ovarian cancer.

CDK inhibitors have also been shown to have potential side effects. For example, the CDK inhibitor nilotinib has been shown to be associated with an increased risk of severe adverse reactions, including a high rate of death. Therefore, when considering the use of CDK inhibitors for cancer treatment, their potential side effects should be carefully evaluated and managed.

In conclusion, Cyclin-dependent kinase inhibitors (CDK Inhibitor), that may be a drug target (or biomarker), have been shown to be effective in treating various types of cancer, including breast, lung, and ovarian cancer. They work by inhibiting the activity of the enzyme CDK, which is a key component of the CDK complex, and results in the inhibition of cell division and growth. While CDK inhibitors have potential cancer therapeutic applications, they have also been identified as potential drug targets or biomarkers, and their use in cancer treatment should be carefully evaluated and managed due to their potential side effects.

Protein Name: Cyclin-dependent Kinase Inhibitor (nonspecified Subtype)

The "Cyclin-dependent kinase inhibitor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Cyclin-dependent kinase inhibitor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets